Imagine losing control of your physical and psychological faculties, even your ability to swallow, while having full mental awareness of what is happening and witnessing complete changes in your personality. For the past 15 years this has been the experience of the members of the Aqui family who have been diagnosed with Huntington’s Disease (HD).
The US Food and Drug Administration has approved deutetrabenazine extended-release tablets (Austedo XR) for tardive dyskinesia or chorea related to Huntington disease.
New once-daily AUSTEDO XR regimen now approved in 6, 12, and 24 mg tablet strengthsAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD) indications1,2AUSTEDO is the only VMAT2 inhibitor with 3-year long-.
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.